M. E. Baffa

Myelodysplasia cutis as the presenting sign of chronic myelomonocytic leukaemia

M. Santucci, E. Antiga, R. Maglie, 2021, Clinical and experimental dermatology.

Rituximab in Mucous Membrane Pemphigoid: A Monocentric Retrospective Study in 10 Patients with Severe/Refractory Disease

E. Antiga, R. Maglie, L. Quintarelli, 2022, Journal of clinical medicine.

Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?

M. Cerinic, S. Guiducci, M. Capassoni, 2022, Frontiers in Immunology.

Severe bullous pemphigoid following Covid‐19 vaccination resistant to rituximab and successfully treated with dupilumab

E. Antiga, R. Maglie, F. Montefusco, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Anti‐β4 integrin autoantibodies in patients with mucous membrane pemphigoid: A retrospective analysis from a tertiary centre in Italy

M. Lulli, T. Hashimoto, E. Antiga, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Sweet Syndrome Following SARS-CoV2 Vaccination

D. Massi, E. Antiga, R. Maglie, 2021, Vaccines.

Interleukin‐36 cytokines are overexpressed in the skin and sera of patients with bullous pemphigoid

L. Mercurio, C. Albanesi, S. Madonna, 2023, Experimental dermatology.

Tralokinumab efficacy in a case of dupilumab‐resistant severe atopic dermatitis complicated by eczema herpeticum

E. Antiga, R. Maglie, L. Quintarelli, 2023, Journal of the European Academy of Dermatology and Venereology.

Alterations of circulating free fatty acids in patients with pemphigus vulgaris

A. Amedei, E. Niccolai, S. Baldi, 2024, Experimental dermatology.